High-dose tocilizumab in combination with methotrexate as a treatment for rheumatoid arthritis was associated with a small but significant increase in adverse events and infection compared to controls; the effect was unclear for tocilizumab monotherapy. Limitations in study numbers and the review process mean that the results should be treated with caution.
Study selection
Randomised controlled trials (RCTs), limited to late phase II or III trials of monotherapy with 8mg/kg tocilizumab and combination therapy with 4mg/kg and 8mg/kg tocilizumab with methotrexate in patients with rheumatoid arthritis were eligible for inclusion. Eligible trial participants had to be adults (≥18 years) with a diagnosis of rheumatoid arthritis (American College of Rheumatology 1987 criteria). The primary outcomes were adverse events including serious infections. One study was excluded due to insufficient patient details.
Half of the studies were of combination therapy; one combined tocilizumab with one of six disease-modifying antirheumatic drugs (DMARDs) of which methotrexate was the most common. Tocilizumab was administered every four weeks and methotrexate weekly, where reported. Two studies were of tocilizumab monotherapy. One study included both combination and monotherapy. The controls for most studies were placebo tocilizumab with methotrexate (and folate in one study); one study used methotrexate alone and another study used placebo tocilizumab plus one or more DMARDs. All of the studies were of active rheumatoid arthritis methotrexate-naive patients; one study was of patients refractory to conventional DMARDs or anti-tumour necrosis factor treatment. Mean age ranged from 49.3 to 54.0 years. Seventy-three to 90.2% of participants in the treatment groups were female. The adverse events most consistently reported and evaluated were: one or more adverse events, serious adverse events, infection and serious infection. Individual definitions were not available and it was assumed that adverse event definitions were consistent. Inconsistently reported adverse events that were not included in the meta-analyses were neutropenia, abnormal liver function tests and altered lipid profile.
Data was extracted in duplicate. Any discrepancies were resolved by checking data and through discussion with other reviewers.
Methods of synthesis
Odds ratios were pooled using fixed-effects models. Χ² and Ι² were used to test for heterogeneity (p<0.1 was considered to be significant heterogeneity). Studies with zero total event were excluded from meta-analyses. Where contingency tables contained zero values, a continuity correction was applied to the relevant tables. Forest plots were produced. Publication bias was estimated using funnel plots. A sensitivity analysis was performed by removing the smallest study.
Results of the review
Six RCTs were identified (3,501 participants, range 127 to 1,220). Most were phase III trials and one was a late phase II trial. All the studies were double-blind RCTs; one was a double-dummy parallel group RCT. The authors concluded that all the studies were of adequate quality as each had accounted for the sources of error that were considered important. Follow-up ranged from 20 to 24 weeks. Loss to follow-up ranged from 0.1% to 31.5%.
Combined therapy with tocilizumab and methotrexate: Risk of at least one adverse event was significantly higher for high-dose tocilizumab than for controls (OR 1.53, 95% CI 1.26 to 1.86; four studies) but not for low-dose versus controls (three studies, Ι²=30%) and high-does versus low-dose tocilizumab (three studies, Ι²=35%). For at least one serious adverse event, there was no significant difference in risk for high-dose versus low-dose tocilizumab (three studies, Ι²=46%) and for low-dose versus controls (three studies). Results for high-dose versus controls (four studies) was not reported due to high heterogeneity (Ι²=59%).
For at least one infection, there was a significant increase in risk for high-dose tocilizumab versus controls (OR 1.30, 95% CI 1.07 to 1.58; three studies). There was no significant increase in risk for low-dose versus controls (two studies) and high-dose versus low-dose tocilizumab (two studies). There was no significant increase in risk of at least one serious infection for high-dose versus controls (four studies), low-dose versus controls (two studies) and high-does versus lowdose tocilizumab (three studies).
Monotherapy with 8mg/kg tocilizumab (high dose): There was no significant increase in risk for 8mg/kg tocilizumab versus controls for at least one serious adverse event (three studies), at least one infection (two studies) and for at least one serious infection (two studies). No results were reported for high-dose monotherapy versus controls for at least one adverse event (three studies) due to high heterogeneity (Ι²=64%).
The main adverse events reported were nasopharyngitis, respiratory tract disorder, skin and soft tissue pathology, and gastrointestinal side effects. The main infections reported were skin, subcutaneous and respiratory tract infections. Except where stated otherwise, heterogeneity was very low (Ι²<1%). Results of the sensitivity analysis were reported. The authors considered that the funnel plots showed no evidence of publication bias.
